Advertisement

Réduction tumorale différée après chimiothérapie néo-adjuvante

  • E. Stoeckle
  • A. Floquet
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Neijt JP, Aartsen EJ, Bouma J et al. (1985) Cytoreductive surgery with or without preceding chemotherapy in ovarian cancer. Prog Clin Biol Res 201: 217–23PubMedGoogle Scholar
  2. 2.
    Wils J, Blijham G, Naus A et al. (1986) Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 4: 1068–73PubMedGoogle Scholar
  3. 3.
    Lawton FG, Redman CWE, Luesley DM et al. (1989) Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 73: 61–5PubMedGoogle Scholar
  4. 4.
    Jacob JH, Gershenson DM, Morris M et al. (1991) Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian carcinoma. Gynecol Oncol 42: 146–50CrossRefPubMedGoogle Scholar
  5. 5.
    Vergote I, De Wever I, Tjalma W et al. (2000) Interval debulking surgery: an alternative for primary surgical debulking? Sem Surg Oncol 19: 49–53Google Scholar
  6. 26.
    Lim JTW, Green JA (1993) Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol 5: 198–202CrossRefGoogle Scholar
  7. 7.
    Surwit E, Childers J, Atlas I et al. (1996) Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynaecol Cancer 6: 356–61Google Scholar
  8. 8.
    Vergote I, De Wever I, Tjalma W et al. (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71: 431–6CrossRefPubMedGoogle Scholar
  9. 9.
    Tate S, Hairai Y, Takeshima N et al. (2005) CA 125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian adenocarcinoma. Gynecol Oncol 96: 143–9CrossRefPubMedGoogle Scholar
  10. 10.
    Recchia F, de Filippis S, Rosseli M et al. (2001) Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaec Oncol 22: 287–91Google Scholar
  11. 11.
    Ansquer Y, Leblanc E, Clough K et al. (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91: 2329–34CrossRefPubMedGoogle Scholar
  12. 12.
    Mazzeo F, Berlière M, Kerger J et al. (2003) Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90: 163–9CrossRefPubMedGoogle Scholar
  13. 13.
    Le T, Faught W, Hopkins L et al. (2005) Primary chemotherapy and adjuvant tumour debulking in the management of advanced staged epithelial ovarian cancer. Communication personnelle, soumis Int J Gynecol CancerGoogle Scholar
  14. 14.
    Schwartz PE, Chambers JT, Makuch R (1994) Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 53: 33–7CrossRefPubMedGoogle Scholar
  15. 15.
    Neijt JP, ten Bokkel Huinink WW, van der Burg ME et al. (1991) Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27: 1367–72PubMedGoogle Scholar
  16. 16.
    Morice P, Brehier-Ollive D, Rey A et al. (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non exposed study; Ann Oncol 14: 74–7PubMedGoogle Scholar
  17. 17.
    Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–59CrossRefPubMedGoogle Scholar
  18. 18.
    Griffiths CT, Parker LM, Fuller AF (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63: 235–40PubMedGoogle Scholar
  19. 19.
    Onnis A, Marchetti M, Padovan P et al. (1996) Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 17: 393–6PubMedGoogle Scholar
  20. 20.
    Schwartz PE, Rutherford TJ, Chambers JT et al. (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol Oncol 72: 93–9CrossRefPubMedGoogle Scholar
  21. 21.
    Shibata K, Kikkawa F, Mika M et al. (2003) Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors. Int J Gynecol Cancer 13: 587–92CrossRefPubMedGoogle Scholar
  22. 22.
    Ushijima K, Ota S, Komai K et al. (2002) Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer Int Surg 87: 185–90Google Scholar
  23. 23.
    Kayikçiog Lu F, Köse MF, Boran N et al. (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11: 466–70Google Scholar
  24. 24.
    Ursic Vrscaj M, Rakar S (2002) Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol 23: 405–10PubMedGoogle Scholar
  25. 25.
    Deval B, Paitel JF, Platini C et al. (2003) Surgery (S): an option for patients with FIGO stage IV ovarian cancer (OC) treated by platinum-paclitaxel-based regimen? A GINECO study. ASCO meeting: abstract 1817Google Scholar
  26. 26.
    Kuhn W, Rutke S, Späthe K et al. (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obxtetrics stage IIIC ovarian carcinoma. Cancer 92: 2585–91CrossRefPubMedGoogle Scholar
  27. 27.
    Morice P, Dubernard G, Rey A et al. (2003) Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 197: 955–63PubMedGoogle Scholar
  28. 28.
    Redman C, Warwick J, Luesley D et al. (1994) Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 101: 142–6PubMedGoogle Scholar
  29. 29.
    Van der Burg M, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–34PubMedGoogle Scholar
  30. 30.
    Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–97CrossRefPubMedGoogle Scholar
  31. 31.
    Eisenkop SM, Spirtos NM, Montag TW et al. (1992) The impact of subspeciality training on the management of advanced ovarian cancer. Gynecol Oncol 47: 203–9CrossRefPubMedGoogle Scholar
  32. 32.
    Junor E, Hole D, McNulty L et al. (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a scottish national study of 1866 patients. Br J Obstet Gynaecol 19: 273–8Google Scholar
  33. 33.
    Van der Burg ME, Van Lent M, Kobierska A et al. (2002) Interval debulking surgery significantly increases the survival and progression-free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecologic Cancer Co-operative Group study. Int Jacobs IJ, Shephard JH et al (Ed). Ovarian Cancer. Oxford University Press, Oxford 299–303Google Scholar
  34. 34.
    Stoeckle E, Paravis P, Floquet A et al. (2004) Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 14: 779–87CrossRefPubMedGoogle Scholar
  35. 35.
    Chan YM, Ng TY, Ngan YS et al. (2002) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88: 9–16Google Scholar
  36. 36.
    Covers AL (2000) A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78: 269–74Google Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • E. Stoeckle
  • A. Floquet

There are no affiliations available

Personalised recommendations